10

15

## WHAT IS CLAIMED IS:

- A method for identifying a compound with a selected activity, comprising:
- (a) determining a change in the expression profile of a selected set of genes in the presence and absence of a first compound having a selected activity,
  - (b) determining a change in the expression profile of the selected set of genes of step (a) in the presence and absence of a second compound,
  - (c) comparing said determined change in expression profile in step (b) with that in step (a)

wherein a determination in step (c) of the same or similar change in said expression profile identifies said second compound as a compound having said selected activity.

- 2. The method of claim 1 wherein said selected activity is antineoplastic activity.
- 3. The method of claim 1 wherein said selected set of genes is present in a cell.
  - 4. The method of claim 1 wherein said expression is transcription.
- 5. The method of claim 1 wherein said change in expression profile is determined by determining synthesis of RNA.
  - 6. The method of claim 1 wherein said change in expression profile is determined by determining polypeptide synthesis.

WO 2004/113502 PCT/US2004/019286

7. The method of claim 1 wherein said selected activity is inducing a physiological change in a cell.

8. The method of claim 1 wherein said selected activity is therapeutic activity.

5

- 9. The method of claim 1 wherein said selected activity is enzyme inhibitory activity.
- 10. The method of claim 1 wherein the compound of step (a) is a topoisomerase II inhibitor.
  - 11. The method of claim 1 wherein the compound of step (a) is a member selected from the group consisting of Camptothecine (S, +), beta-Lapachone, Suramin sodium salt, Aclacinomycin A from Streptomyces galilaeus, Mitoxantrone dihydrochloride, Etoposide, Doxorubicin hydrochloride, Aurintricarboxylic acid, Epirubicin hydrochloride, and m-AMSA hydrochloride.
    - 12. The method of claim 3 wherein the cell is a colon cell.

20

15

- 13. The method of claim 12 wherein said cell is a cancer cell.
- 14. The method of claim 3 wherein the cell is a recombinant cell engineered to express said selected set of genes.

25

- 15. The method of claim 14 wherein said recombinant cell does not express said selected set of genes absent said engineering.
- 16. The method of claim 3 wherein said selected set of genes is part of30 the genome of said cell.

WO 2004/113502 PCT/US2004/019286

17. A related gene set comprising genes whose polynucleotide sequences correspond to the sequences of SEQ ID NO: 1-12.

- 18. The method of claim 1 wherein said determined genes are in the gene set of claim 17.
  - 19. A compound identified as having therapeutic activity by the method of claim 1.
- 10 20. A compound identified as having anti-neoplastic activity by the method of claim 1.
  - 21. A compound identified as having enzyme inhibitory activity by the method of claim 1.
  - 22. A method for treating a disease comprising administering to an animal afflicted with said disease of a therapeutically effective amount of the compound of claim 19.
- 20 23. A method for treating cancer comprising administering to an animal afflicted with cancer of a therapeutically effective amount of the compound of claim 20.
  - 24. A method for identifying a related gene set comprising:

15

30

- contacting a cell with each of a plurality of compounds having common biological activity and determining a change in the expression of a plurality of genes of said cell as a result of said contacting where contacting with each of said plurality of compounds results in the same relative changes of expression of said genes and thereby identifying said genes as a related gene set.
  - 25. The method of claim 24 wherein said biological activity is therapeutic activity.

26. The method of claim 24 wherein said biological activity is enzyme inhibitory activity.

- 27. The method of claim 24 wherein said biological activity is anti-5 neoplastic activity.
  - 28. The method of claim 24 wherein said plurality of compounds are topoisomerase II inhibitors.
- 29. The method of claim 24 wherein said plurality of compounds comprise members selected from the group consisting of Camptothecine (S, +), beta-Lapachone, Suramin sodium salt, Aclacinomycin A from Streptomyces galilaeus, Mitoxantrone dihydrochloride, Etoposide, Doxorubicin hydrochloride, Aurintricarboxylic acid, Epirubicin hydrochloride, and m-AMSA
  15 hydrochloride.
  - 30. A method for producing test data with respect to a biological activity of a compound comprising:
- (a) contacting a cell with each of a plurality of compounds exhibiting similar biological activity and determining a change in the expression of a plurality of genes of said cell as a result of said contacting whereby the relative changes in expression of said genes together forms a gene expression profile;

25

- (b) contacting a compound different from that of (a) with the determined genes of (a) and determining a change in expression of said determined genes as a result of said contacting whereby the relative changes in expression of said determined genes together forms the gene expression profile of (a) thereby identifying a biologically active compound; and
- (c) producing test data with respect to the gene modulating activity 30 of said compound based on the gene expression profile indicating biological activity.

-WO 2004/113502 PCT/US2004/019286

31. A recombinant cell expressing a related gene set identified by the method of claim 24.

32. A recombinant cell expressing the related gene set of claim 17.